AU3651102A - Composition containing statins and calcium for improved cardiovascular health - Google Patents

Composition containing statins and calcium for improved cardiovascular health

Info

Publication number
AU3651102A
AU3651102A AU3651102A AU3651102A AU3651102A AU 3651102 A AU3651102 A AU 3651102A AU 3651102 A AU3651102 A AU 3651102A AU 3651102 A AU3651102 A AU 3651102A AU 3651102 A AU3651102 A AU 3651102A
Authority
AU
Australia
Prior art keywords
calcium
composition containing
cardiovascular health
improved cardiovascular
containing statins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU3651102A
Inventor
Adrianne Bendich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU3651102A publication Critical patent/AU3651102A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU3651102A 2000-11-29 2001-11-29 Composition containing statins and calcium for improved cardiovascular health Pending AU3651102A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25389900P 2000-11-29 2000-11-29
PCT/US2001/044734 WO2002043659A2 (en) 2000-11-29 2001-11-29 Composition containing statins and calcium for improved cardiovascular health

Publications (1)

Publication Number Publication Date
AU3651102A true AU3651102A (en) 2002-06-11

Family

ID=22962156

Family Applications (1)

Application Number Title Priority Date Filing Date
AU3651102A Pending AU3651102A (en) 2000-11-29 2001-11-29 Composition containing statins and calcium for improved cardiovascular health

Country Status (6)

Country Link
EP (1) EP1339429A4 (en)
JP (1) JP2004514684A (en)
AU (1) AU3651102A (en)
CA (1) CA2427618A1 (en)
MX (1) MXPA03004818A (en)
WO (1) WO2002043659A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004006919A1 (en) * 2002-07-11 2004-01-22 Sankyo Company, Limited Medicinal composition for mitigating blood lipid or lowering blood homocystein
JP4611622B2 (en) * 2002-07-11 2011-01-12 第一三共株式会社 Pharmaceutical composition for improving blood lipid or reducing blood homocysteine
CA2499501A1 (en) * 2002-09-27 2004-04-08 Martek Biosciences Corporation Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
NZ539625A (en) * 2002-09-27 2007-11-30 Martek Biosciences Corp Improved glycemic control for Prediabetes and/or Diabetes Type II Using Docosahexaenoic Acid
FR2847472B1 (en) * 2002-11-22 2006-08-11 Synergia NOVEL PHARMACEUTICAL COMPOSITIONS, IN PARTICULAR FOR THE PREVENTION OF CARDIOVASCULAR PATHOLOGIES
DE10261067A1 (en) * 2002-12-24 2004-08-05 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Cholesterol-lowering agent containing an n-3 fatty acid
CA2549116A1 (en) * 2003-12-23 2005-07-07 Medicure International Inc. Combination therapies employing a composition comprising a hmg coa reductase inhibitor and a vitamin b6 related compound
ITRM20040395A1 (en) * 2004-08-03 2004-11-03 Sigma Tau Ind Farmaceuti COMPOSITION INCLUDING STATINES AND FATTY ACIDS OMEGA 3.
KR20070038553A (en) * 2004-08-06 2007-04-10 트렌스폼 파마수티컬스 인코퍼레이티드 Novel statin pharmaceutical compositions and related methods of treatment
EP1781118A1 (en) * 2004-08-23 2007-05-09 Unilever N.V. Composition comprising statin
ES2255426B1 (en) * 2004-10-19 2007-08-16 Gp Pharm, S.A. PHARMACEUTICAL FORMULATION THAT INCLUDES MICROCAPSULES OF STATINS SUSPENDED IN ESTER ALKYLS OF POLYINSATURATED FATTY ACIDS (PUFA).
KR101356335B1 (en) * 2004-12-06 2014-02-06 릴라이언트 파마슈티컬스 인코퍼레이티드 Omega-3 fatty acids and dyslipidemic agent for lipid therapy
US20060135610A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Cardiovascular compositions
RU2008108078A (en) 2005-08-04 2009-09-10 Трансформ Фармасьютикалз, Инк. (Us) NEW PREPARATORY FORMS INCLUDING PHENOFIBRATE AND STATIN, AND RELATED METHODS OF TREATMENT
JP5113527B2 (en) * 2005-11-11 2013-01-09 持田製薬株式会社 Jelly composition
EP2081550B2 (en) * 2006-03-09 2021-05-26 Reliant Pharmaceuticals, Inc. Coating capsules with active pharmaceutical ingredients
US8784886B2 (en) * 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
ITMI20072142A1 (en) * 2007-11-08 2009-05-09 Yervant Zarmanian PHARMACEUTICAL COMPOSITIONS CONTAINING STATIN AND OMEGA-3 FATTY ACID DERIVATIVES
EP2308493A4 (en) * 2008-07-07 2013-05-01 Mochida Pharm Co Ltd Ameliorating or therapeutic agent for dyslipidemia
GB0818473D0 (en) 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
GB0818472D0 (en) * 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
ITFI20080243A1 (en) * 2008-12-15 2010-06-16 Valpharma Sa FORMULATIONS FOR ORAL ADMINISTRATION OF OMEGA POLIENOIC FATTY ACIDS IN COMBINATION WITH NATURAL OR SEMI-SYNTHETIC STATINES.
ES2661812T3 (en) * 2009-10-16 2018-04-04 Mochida Pharmaceutical Co., Ltd. Compositions
KR20120104270A (en) 2009-12-23 2012-09-20 데피안떼 파마슈띠까 에스.에이. Combination composition useful for treating cardiovascular diseases
WO2012085671A2 (en) * 2010-12-21 2012-06-28 Omegatri As Antioxidants in fish oil powder and tablets
KR101310710B1 (en) * 2011-03-23 2013-09-27 한미약품 주식회사 Oral complex composition comprising omega-3 fatty acid ester and hmg-coa reductase inhibitor
FR3007985A1 (en) * 2013-07-02 2015-01-09 Internat Nutrition Res Company MEDICAMENT FOR THE PREVENTION AND TREATMENT OF CARDIOMETABOLIC RISK FACTORS, IN PARTICULAR CARDIOVASCULAR DISEASES, PRE DIABETES, TYPE II DIABETES AND HEPATIC STEATOSIS
FR3007986A1 (en) * 2013-07-02 2015-01-09 Internat Nutrition Res Company MEDICAMENT FOR CONTROLLING INFERTILITY AND SUB-FERTILITY IN PARTICULAR WITHIN METABOLIC FERTILITY OR INFERTILITY
FR3007987A1 (en) * 2013-07-02 2015-01-09 Internat Nutrition Res Company MEDICAMENT FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS AND METABOLIC OVERVOLTAGE
EP3046552A1 (en) * 2013-07-02 2016-07-27 International Nutrition Research Company Composition involved in regulating energy cycle, inflammation and insulin resistance dysfunctions, and use thereof particularly in cardiometabolic diseases
CN109195596A (en) * 2016-04-14 2019-01-11 迈克尔·露西 Composition and its application method

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940727A (en) * 1986-06-23 1990-07-10 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
CA2222278C (en) * 1995-06-06 2008-05-13 Campbell Soup Company Mineral supplements for dietetic food
AU732465B2 (en) * 1996-04-17 2001-04-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
DE69622722T2 (en) * 1996-11-20 2003-02-27 Nutricia Nv Dietary composition containing fats for the treatment of metabolic syndrome

Also Published As

Publication number Publication date
WO2002043659A3 (en) 2002-09-06
MXPA03004818A (en) 2003-09-10
EP1339429A2 (en) 2003-09-03
CA2427618A1 (en) 2002-06-06
JP2004514684A (en) 2004-05-20
EP1339429A4 (en) 2007-03-14
WO2002043659A2 (en) 2002-06-06

Similar Documents

Publication Publication Date Title
AU3651102A (en) Composition containing statins and calcium for improved cardiovascular health
HUP0301745A3 (en) Cyclopentanoindoles, compositions containing such compounds and their use
GB0119935D0 (en) Perfume containing composition
HUP0401333A3 (en) Spiropyrazole compounds and pharmaceutical compositions containing them
HUP0400589A3 (en) Colostrum-based composition
SG99895A1 (en) Proanthocyanidin-containing composition
IL130882A0 (en) Sorbent composition
EP1393726A4 (en) Compositions for improving mental concentration
GB0023891D0 (en) Composition
EP1270611A4 (en) Composition
GB2368014B (en) Pharmaceutical composition containing citalopram
HUP0303936A3 (en) Novel composition and use
GB0022473D0 (en) Composition
MXPA03004817A (en) Dietary composition containing conjugated linoleic acid and calcium for improved health.
AU2002236511A1 (en) Composition containing statins and calcium for improved cardiovascular health
IL156547A0 (en) Pharmaceutical composition containing citalopram
EP1267814A4 (en) Composition
GB0122658D0 (en) Composting container
GB0019768D0 (en) Preservative compounds and compositions
SG88779A1 (en) Food modification method and composition therefor
GB0003101D0 (en) Novel composition
GB0003102D0 (en) Novel composition
GB0122906D0 (en) Compounds and compositions
GB0018854D0 (en) Novel composition and use
GB0013236D0 (en) Novel composition and use